The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Abstract
Discontinuation symptoms are recognised with tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs) and miscellaneous antidepressants. A wide variety of symptoms have been described, differing somewhat between antidepressant classes, and several symptom clusters or discontinuation syndromes appear to exist. A common feature is onset within a few days of stopping the antidepressant or, less commonly, reducing the dosage. Discontinuation syndromes are clinically relevant as they are common, can cause significant morbidity, can be misdiagnosed leading to inappropriate treatment and can adversely effect future antidepressant compliance. Preventative strategies include tapering antidepressants prior to stoppage and educating patients and healthcare professionals to ensure that antidepressants are taken consistently and not stopped abruptly. Most reactions are mild and short-lived and require no treatment other than patient reassurance. Severe cases can be treated symptomatically or the antidepressant can be reinstated before being gradually withdrawn. Reinstatement usually leads to symptom resolution within 24 hours. Some individuals require very conservative tapering schedules to prevent the re-emergence of symptoms. With SSRIs and venlafaxine another strategy to consider is switching to fluoxetine, which may suppress the discontinuation symptoms, but which has little tendency to cause such symptoms itself. Neonatal discontinuation symptoms can follow maternal use of antidepressants during pregnancy and possibly breast feeding. The patient and doctor must take this into consideration when making prescribing decisions. Discontinuation symptoms have received little systematic study with the result that most of the recommendations made here are based on anecdotal data or expert opinion. Research is needed to provide a firm evidence base for future recommendations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, it has been suggested that gradual discontinuation can reduce both rebound insomnia [84, 85] and rebound anxiety [1].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [84]
In the citing paper
“It is now suspected that antidepressant withdrawal syndrome is more common and severe than earlier presumed, affecting roughly 30–50% of those who attempt to stop their treatment.12,13,23,24”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [24]
In the citing paper
“With new-generation antidepressants, it has been widely observed that risk of withdrawal emerges after the drugs have been taken for 1 to 2 months.24,39”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [24]
In the citing paper
“We now have increasing evidence for postwithdrawal disorders with SSRI long-term use [6,15,16,26,37] .”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“Persistent postwithdrawal disorders have been described with different classes of CNS drugs (e.g.protracted insomnia for alcohol and benzodiazepine withdrawal [10,36] and major depression/dysphoria for cocaine and amphetamine withdrawal [10,23] ), and even more so with specific drugs (e.g.quetiapine and paroxetine) within a drug class [6,15,16,33] .”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“Data from controlled trials [15,20,29] , case reports [16] , and online patient reports [26] show that paroxetine is most likely to be associated with new withdrawal symptoms, and fluoxetine the least.”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“Rebound anxiety [2,14] and rebound panic [15] were then reported with abrupt benzodiazepine discontinuation [9] .”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“According to most studies [1,15,16,20,29] , even with gradual tapering, withdrawal symptoms still occur.”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“They may resemble rebound symptoms being more severe than the original symptoms, but these disorders persist at least 6 weeks in contrast to rebound symptoms and [6,15,16,26,37] .”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“Given the evidence for the high risk of disabling withdrawal with paroxetine”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“thought to be related to noradrenergic and cholinergic supersensitivity [15,35]”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
In the citing paper
“Persistent postwithdrawal panic disorder [15,38] has been shown to occur following withdrawal of paroxetine, and paroxetine has also been associated with other postwithdrawal disorders [6,15,16] .”
From New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) · cites this paper as [15]
Citations
Cites
Birth Outcomes in Pregnant Women Taking Fluoxetine
Chambers, C., Johnson, K. A., Dick, L. M., Felix, R. J., & Jones, K. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351402 · Cited by 735
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Priest, R. G., Vize, C., Roberts, A., Roberts, M., & Tylee, A. (1996) · BMJ · doi:10.1136/bmj.313.7061.858 · Cited by 385
Serotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.10.1485 · Cited by 263
Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261
Pharmacologic Treatment of Depression During Pregnancy
Wisner, K. L. (1999) · JAMA · doi:10.1001/jama.282.13.1264 · Cited by 250
Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine
D, M. F. M., Mulroy, R., Alpert, J. E., Nierenberg, A. A., & Rosenbaum, J. F. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.12.1760 · Cited by 198
Withdrawal syndromes associated with antipsychotic drugs
Gárdos, G., Jo, C., & Tarsy, D. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.11.1321 · Cited by 192
Michelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181
Research works printed but not linked: 25
- Ceccherini-Nelli, 1993, Am J Psychiatry, 150, 165
- Diamond, 1989, Psychopharmacol Bull, 25, 209
- Law, 1981, Am J Psychiatry, 118, 647
- Geller, 1987, J Clin Psychopharmacol, 7, 252
- Liskin, 1984, J Clin Psychopharmacol, 5, 46
- Halle, 1993, J Psychiatry Neurosci, 18, 49
- Einbinder, 1995, Am J Psychiatry, 152, 1253
- Black, 1993, J Clin Psychiatry, 54, 146
- Louie, 1996, Am J Psychiatry, 153, 1652
- Schatzberg, 1997, J Clin Psychiatry, 58, 5
- DArcy, 1993, Int Pharm J, 7, 140
- Stoukides, 1991, Am J Psychiatry, 148, 1263
- Kasantikul, 1995, J Med Assoc Thai, 78, 53
- Parker, 1998, Aust N Z J Psychiatry, 32, 292
- Agelink, 1997, Am J Psychiatry, 154, 1473
- Wolfe, 1997, Am Fam Physician, 56, 452
- 1996, Aust Adverse Drug Reactions Bull Nov, 15, 3
- Frost, 1995, Am J Psychiatry, 152, 810
- Stem, 1980, J Clin Psychiat, 41, 66
- Mander, 1998, Lancet, 339, 15
- Rosenblatt, 1996, Curr Affect Illness, 15, 8
- Phillips, 1995, Am J Psychiatry, 152, 645
- Eggermont, 1972, Acta Paediatr Belg, 26, 197
- 1997, Austral Adverse Drug Reactions Bull Nov, 16, 14
- Dahl, 1997, Br J Psychiatry, 171, 91
Cited by
Sorted by citations
Items 101–200 of 213
Review of sertraline in post-traumatic stress disorder
Schwartz, A. C., & ROTHBAUM, B. O. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.10.1489 · Cited by 13
Getting the balance right: Established and emerging therapies for major depressive disorders
Vezmar (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s10485 · Cited by 12
Antidepressant Discontinuation Syndrome
Kim, S. H., Kim, Y. S., & Kang, U. G. (2024) · 신경정신의학 · doi:10.4306/jknpa.2024.63.2.104 · Cited by 12
Takakura, K., Nagaya, M., Mori, M., Koga, H., Yoshitake, S., & Noguchi, T. (2006) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0603400108 · Cited by 12
SSRI withdrawal syndrome in children and adolescents: a narrative literature review
Khan, Y. S., Khoodoruth, M. A. S., Albobali, Y., & Haddad, P. M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2224557 · Cited by 12
Self-citationCAMPBELL, N. D. (2013) · Duke University Press eBooks · doi:10.1215/9780822395874-010 · Cited by 11
Senese, N. B., & Rasenick, M. M. (2021) · Molecular Pharmacology · doi:10.1124/molpharm.120.000226 · Cited by 10
Wang, H., Luo, W.-L., Zeng, N.-X., Li, H., Li, L., Yan, C., & Wu, L. (2021) · Pharmaceutical Biology · doi:10.1080/13880209.2021.1954666 · Cited by 10
Usami, M., Iwadare, Y., Watanabe, K., Ushijima, H., Kodaira, M., Okada, T., Sasayama, D., Sugiyama, N., & Saito, K. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.03.023 · Cited by 10
Cucci, M. D., Chester, K. W., & Hamilton, L. A. (2022) · Critical Care Medicine · doi:10.1097/ccm.0000000000005415 · Cited by 9
Piotrowski, P., Gondek, T. M., Rymaszewska, J., Beszłej, J. A., Czachowski, S., Parmentier, H., & Kurpas, D. (2017) · Family Medicine & Primary Care Review · doi:10.5114/fmpcr.2017.69300 · Cited by 9
Medical and Psychiatric Causes of Episodic Vestibular Symptoms
Meurer, W. J., Low, P. A., & Staab, J. P. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.04.007 · Cited by 11
Tranylcypromine Discontinuation Symptoms and Withdrawal Delirium
Freudenmann, R. W., Baumgarten, E., Hawlik, A. E., Schönfeldt‐Lecuona, C., & Gahr, M. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31829465df · Cited by 8
Adverse Neurologic Effects of Medications Commonly Used in the Intensive Care Unit
Voils, S. A., Human, T., & Brophy, G. M. (2014) · Critical Care Clinics · doi:10.1016/j.ccc.2014.06.009 · Cited by 8
Recognizing depression in late life
Edlund, B. J., Lauerer, J., & Drayton, S. J. (2015) · The Nurse Practitioner · doi:10.1097/01.npr.0000459729.92650.ce · Cited by 8
Venlafaxine Withdrawal Syndrome
Baboolal, N. S. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117427.05703.f2 · Cited by 8
Prevention of the serotonin reuptake inhibitor discontinuation syndrome
Sher, L. (2002) · Medical Hypotheses · doi:10.1016/s0306-9877(02)00127-5 · Cited by 8
The importance of long-term tolerability in achieving recovery
Baldwin, D. S. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600552552 · Cited by 7
Challenging Normative Orthodoxies in Depression: Huxley's Utopia or Dante's Inferno?
Cutcliffe, J. R., & Lakeman, R. (2009) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2009.06.004 · Cited by 7
When the Bough Breaks: Rethinking Treatment Strategies for Perinatal Depression
Rosenquist, S. E. (2013) · American Journal of Clinical Hypnosis · doi:10.1080/00029157.2012.723284 · Cited by 7
PLACEBOS OR PROSTHESES FOR THE WILL?
Raikhel, E. (2013) · Duke University Press eBooks · doi:10.1215/9780822395874-008 · Cited by 7
Medication dependence and anxiety
Moltke, L. L., & Greenblatt, D. J. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.3/lvonmoltke · Cited by 7
Fluoxetine Dependence in a Former Amineptine Abuser
Taïeb, O., Larroche, C., Dutray, B., Baubet, T., & Moro, M. R. (2004) · American Journal on Addictions · doi:10.1080/10550490490512898 · Cited by 7
Saris, A. J. (2013) · Duke University Press eBooks · doi:10.1215/9780822395874-011 · Cited by 6
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Cucci, M. D., Cunningham, B. S., Patel, J. S., Shimer, A. T., Mofleh, D. I., & Mullen, C. L. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020935589 · Cited by 5
Schüll, N. D. (2013) · Duke University Press eBooks · doi:10.1215/9780822395874-003 · Cited by 5
Carr, E. S. (2013) · Duke University Press eBooks · doi:10.1215/9780822395874-007 · Cited by 5
(2005) · CRC Press eBooks · doi:10.1201/b14455-5 · Cited by 5
Zhang, Z., Yang, Q., Chen, M., Yang, W., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1385651 · Cited by 4
Healthcare Providers' Perspectives on Antidepressant Discontinuation: A Focus Group Study
Bouarfa, S., Göttgens, W., Ligthart, S. A., Maarsingh, O. R., Vinkers, C. H., Ruhé, H. G., Bet, P. M., & Hugtenburg, J. G. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70051 · Cited by 5
Antidepressant Use During Hospice Patients’ Final Months on Routine Home Care
Crampton, E., & Weisse, C. S. (2022) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091221134028 · Cited by 4
Deprescribing and Its Application to Psychiatry
Gupta, S., & Miller, R. A. (2018) · Springer eBooks · doi:10.1007/978-3-030-02732-2_6 · Cited by 4
Antidepressant Discontinuation Syndrome: A Common but Underappreciated Clinical Problem
Rizkalla, M. N., Kowalkowski, B., & Prozialeck, W. C. (2020) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2020.030 · Cited by 4
“You Can Always Tell Who’s Using Meth”
Garriott, W. (2013) · Duke University Press eBooks · doi:10.1215/9780822395874-009 · Cited by 4
Venlafaxine deprescribing and thyroid function
Zarowitz, B. J. M., & Jain, S. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2803 · Cited by 3
Velez, L. I., Feng, S.-Y., & Neerman, M. F. (2010) · Clinical Pediatrics · doi:10.1177/0009922810366734 · Cited by 3
Side Effects of Psychotropic Medications
Huffman, J. C., & Stern, T. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04743-2.50053-6 · Cited by 4
A FEW WAYS TO BECOME UNREASONABLE:
Meyers, T. (2013) · Duke University Press eBooks · doi:10.1215/9780822395874-004 · Cited by 3
Garcia, A. (2013) · Duke University Press eBooks · doi:10.1215/9780822395874-002 · Cited by 3
van Geffen, E. C. G. (2004) · Utrecht University Repository (Utrecht University) · Cited by 3
Biological Treatments of Mood Disorders
Ebmeier, K. P., Berge, A., Semple, D. M., Shah, P. J., & Steele, J. D. (2004) · Wiley eBooks · doi:10.1002/9780470696385.ch7 · Cited by 3
Clinical practice guideline for assessment and management of depression in India
Tripathi, A., Shukla, R., Kar, S. K., Gupta, S., Saran, P., Pattojoshi, A., & Rao, T. (2026) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_1321_25 · Cited by 4
Complications liées à l’utilisation périopératoire des médicaments antidépresseurs
Rozec, B. R., Cinotti, R., & Blanloeil, Y. (2011) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2011.07.012 · Cited by 2
PHARMACEUTICAL EVANGELISM AND SPIRITUAL CAPITAL:
Hansen, H. (2013) · Duke University Press eBooks · doi:10.1215/9780822395874-005 · Cited by 2
The Ongoing Emergence of Technology in Healthcare to Enhance Patient Outcomes
Corbett, D., Hall, M., Hanna, L., & Barry, H. E. (2023) · CRC Press eBooks · doi:10.1201/9781003224464-13 · Cited by 2
Effets secondaires des antidépresseurs
Lôo, H., & Olié, J. (2004) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/j.emcps.2004.05.003 · Cited by 2
Scientific basis of the homeopathic healing principle in modern pharmacology
Teixeira, M. Z. (2017) · Revista de Homeopatia · Cited by 2
Pharmacologic-Enhanced Approaches for the Anxiety Disorders
Avari, J. M., Cohen, M. G., Hatziergati, D., & Walkup, J. T. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108235655.008 · Cited by 2
An Age-Friendly Approach to Medication Optimization
Chou, J., & Courtin, S. O. (2025) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2025.340 · Cited by 1
Treatment of the psychiatric patient
Chepenik, L. G., & Mallory, M. N. S. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139088077.026 · Cited by 2
Treatment ofpsychiatric illness in the emergency department
Nordstrom, K. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139088077.032 · Cited by 1
Karataş, Y., Khan, Z., & Khan, F. U. (2022) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.1112770 · Cited by 1
Gottesman-Katz, L., Borlack, R. E., & Khlevner, J. (2022) · Springer eBooks · doi:10.1007/978-3-031-15229-0_44 · Cited by 1
Deprescribing Antidepressant Medications in Major Depressive Disorder
Gupta, S., Miller, R. A., & Cahill, J. D. (2019) · doi:10.1093/med/9780190654818.003.0008 · Cited by 1
Outcomes in the Treatment of Major Depressive Disorder
Thase, M. E., & Koenig, A. M. (2009) · Medical psychiatry · doi:10.3109/9781420084887.002 · Cited by 1
Bilden, E. F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-05472-0.00149-3 · Cited by 1
Medication-Induced Movement Disorders and Other Adverse Effects of Medication
(2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890425787.medication_induced_movement_disorders · Cited by 2
Antidepressant-Antianxiety Agents
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_4 · Cited by 1
Biological Treatment of Mood Disorders
Allan, C. L., Topiwala, A., Ebmeier, K. P., Semple, D. M., & Steele, J. D. (2013) · Wiley eBooks · doi:10.1002/9781118316153.ch6 · Cited by 1
Relapse prevention and antidepressants
Curtin, F., & Schulz, P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13709-9 · Cited by 1
Medical Management of Co-Morbid Anxiety and Substance Use Disorder
Marshall, E. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-74290-8_12 · Cited by 1
Antidepressants Discontinuation Syndrome
송후림, Sup, W. Y., & Bahk, W. (2010) · 대한정신약물학회지 · Cited by 1
Martin, E. (2013) · Duke University Press eBooks · doi:10.1215/9780822395874-012 · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
(2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.550 · Cited by 1
(2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23672-3.00005-6 · Cited by 1
La marchandisation de la depression : la prescription des ISRS aux femmes*
Currie, J., Rochon, A., & Prozac, L. (2005)
Murphy, M. P. (2006) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)
Pereira, C. A. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2014.tde-07072014-110258
Indeling en bijwerkingen van psychofarmaca
LOONEN, A. J. M. (2004) · Neuropraxis · doi:10.1007/bf03079021
Understanding the use of antidepressants
Haddad, M., & Young, N. (2011) · Practice Nursing · doi:10.12968/pnur.2011.22.7.347
Patient Management Exercise for Psychosomatic Medicine
Cook, I. A. (2009) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.7.3.foc343
VENLAFAXINE INDUCED DELIRIUM IN A WITHDRAWAL SYNDROME
Ifteni, P. I., Teodorescu, A., Taran, L. M., & Burtea, V. (2013) · Bulletin of the Transilvania University of Brasov Series VI Medical Sciences
USE OF PSYCHOPHARMACOLOGICAL AGENTS FOR FUNCTIONAL
Clouse, R. E. (2005)
Ali, L. (2013) · HEC National Digital Library
Koch, H. J. (2015) · Acta Medica Medianae · doi:10.5633/amm.2015.0308
Outcomes in the Treatment of Major Depressive Disorder
Thase, M. E., & Koenig, A. M. (2009) · doi:10.3109/9781420084887-4
Patient with a Psychiatric Condition
Yunas, I. (2016) · doi:10.1002/9781118298565.ch19
Antidépresseurs : aspects thérapeutiques
Souaiby, L., Gauthier, C., Poirier, M., Olié, J., Gaillard, R., & Krebs, M. (2016) · Time to knit · doi:10.1016/s0246-1072(16)75752-x
Lauderdale, S. (2009) · The American Pharmacists Association eBooks · doi:10.21019/9781582121055.ch70
Schoeman, J. C. (2015) · Boloka Institutional Repository (North-west University)
Haddad, P. M. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32002-2
Self-citationMood Disorders (Major Depression, Bipolar Disorder)
Nagaratnam, N., Nagaratnam, K., & Cheuk, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-33434-9_73
Леоновна, Г. Т., Крайнева, В. А., Вальдман, Е. А., Гудашева, Т. А., Олеговна, К. С., & Середенин, С. Б. (2018) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf16128-33
Bauer, M., Whybrow, P. C., Angst, J., Versiani, M., & Möller, H. (2009) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832009000800002
Effets secondaires des antidépresseurs
Löo, H., & Olié, J. (2004) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(04)40828-1
(2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.276
(2013) · Duke University Press eBooks · doi:10.1215/9780822395874-013
Was ist zu tun: Interventionen
(2008) · Springer eBooks · doi:10.1007/978-3-540-68327-8_5
(2010) · Wiley eBooks · doi:10.1002/9781118269954.refs
Mood Disorders (Major Depression, Bipolar Disorder)
Nagaratnam, N., Nagaratnam, K., & Cheuk, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-32700-6_73-1
(2022) · Elsevier eBooks · doi:10.1016/b978-3-437-23673-0.00005-7
Fixley, J. E., & Tadel, M. C. (2011) · Springer eBooks · doi:10.1007/978-0-85729-498-2_30
&NA; (2007) · Drugs & Therapy Perspectives · doi:10.2165/00042310-200723070-00008
(2015) · Elsevier eBooks · doi:10.1016/b978-3-437-23671-6.00005-5
Antidepressant discontinuation syndromes: common, under-recognised and not always benign
&NA; (2001) · Drugs & Therapy Perspectives · doi:10.2165/00042310-200117200-00004
Untoward side effects of psychiatric drugs
Sharma, M. S., Passos, I. C., & Carvalho, A. F. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198746638.003.0020
The Sad Side of Happy Pills: A Case Study on Psychiatric Medication Across a Woman’s Lifespan?
Tochkov, K., & Williams, N. (2023) · Advances in Social Sciences Research Journal · doi:10.14738/assrj.105.14774
Psikologlar ve Psikolojik Danışmanlar için Psikofarmakolojiye Giriş
Özen, Y. (2024) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3078
Metadata
- Authors
- Haddad, P. M.
- Corresponding author
- Haddad, Peter M.
- ORCID
- Haddad, Peter M.
- Venue
- Drug Safety
- Published
- 2001
- Volume
- 24
- Issue
- 3
- Pages
- 183-197
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W1593032895
- Cited by
- 214
- References
- 99
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 10 · 2021: 5 · 2020: 5 · 2019: 5 · 2018: 9 · 2017: 8 · 2016: 7 · 2015: 10 · 2014: 7 · 2013: 24 · 2012: 4
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- antidepressant discontinuation syndrome, antidepressant withdrawal symptoms, selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, antidepressant tapering, fluoxetine, venlafaxine, breastfeeding
- MeSH terms
- Animals, Antidepressive Agents, Antidepressive Agents, Tricyclic, Humans, Monoamine Oxidase Inhibitors, Patient Compliance, Substance Withdrawal Syndrome, Syndrome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
